Seagen Announces Plans to Expand Biomanufacturing Capacity in the Pacific Northwest to Support its Growing Portfolio of Transformative Cancer Drugs

BOTHELL, Wash.–(BUSINESS WIRE)–Seagen inc. (Nasdaq: SGEN) today announced plans to build a new facility in Everett, Wash. to expand the company’s biomanufacturing capacity and allow the company greater control and flexibility on the production of its drugs to treat cancer. The 270,000 square foot facility will be built north of the company’s US headquarters in Bothell, Washington. Seagen plans to make the facility operational in 2024 and eventually employ up to 200 highly skilled workers to produce drugs for clinical trials and the commercial market.

“In cancer research and development, Seagen must continue to demonstrate agility and flexibility, particularly in manufacturing, to advance our promising pipeline of drugs for people with cancer and bring these drugs to patients. as quickly as possible,” said Clay Siegall, Ph.D., President and CEO, Seagen. “This new biomanufacturing facility is another way for us to grow and expand our operations while positioning ourselves to attract high-level talent to advance our business priorities.”

The new biomanufacturing facility is a “greenfield” project, built from the ground up in a modern production facility to manufacture advanced drugs. Seagen plans to manufacture antibody drugs (also called biologics) in the new, fully integrated facility for the commercial market and for use in clinical sites around the world. The new facility will complement Seagen’s existing manufacturing site in the Bothell region. This project will create up to 150 new jobs during the initial construction of the building shell and core.

Seagen markets four therapies used in the treatment of Hodgkin’s lymphoma and urothelial (bladder), breast and cervical cancers. In research and development, Seagen is advancing more than 17 programs, including approved products and a deep and diverse early-stage and late-stage pipeline spanning a range of solid tumors and hematological malignancies.

As a global biotech company, Seagen employs more than 2,800 people worldwide, including more than 1,600 in the Pacific Northwest.

About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and markets transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has offices in California, Canada, Switzerland, and the European Union. For more information on our marketed products and strong pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward-looking statements

Some of the statements made in this press release are forward-looking, such as those relating to plans for the construction, development and operation of the referenced facility, including the expected timing and potential uses of the facility, and other statements that are not historical. realities. Actual results or developments may differ materially from those projected or implied by such forward-looking statements. Factors that could cause such a difference include the potential for delays or difficulties in constructing and developing the facility, obtaining and installing necessary equipment, meeting regulatory requirements, or operating the facility. and the risk related to the COVID-19 pandemic. Further information about the risks and uncertainties facing Seagen is contained in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.